Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines

Genes Chromosomes and Cancer

Volumn 48, Issue 5, 2009, Pages 419-428

  Greshock, J ^a   Nathanson, K ^b   Medina, A ^b   Ward, M R ^b   Herlyn, M ^c   Weber, B L ^a   Zaks, T Z ^a,d  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WISTAR INSTITUTE   (United States)

^d CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; BRAF PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL TRANSFORMATION; CORRELATION ANALYSIS; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; TUMOR CLASSIFICATION; CHI SQUARE DISTRIBUTION; CHROMOSOME ABERRATION; DNA MICROARRAY; GENE DOSAGE; GENETICS; MUTATION; NUCLEIC ACID HYBRIDIZATION; ONCOGENE RAS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; CHROMOSOME ABERRATIONS; GENE DOSAGE; GENES, RAS; HUMANS; MELANOMA; MUTATION; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 65349136425     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20651     Document Type: Article

References (40)

1. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Bran- nigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. 2005. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092.
2. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR. 2006. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and geneexpression subtypes of breast cancer. Genes Chromosomes Cancer 45:1033-1040.
3. Brown MP, Grundy WN, Lin D, Cristianini N, Sugnet CW, Furey TS, Ares M, Jr. Haussler D. 2000. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA 97:262-267.
4. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. 2008. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 68:3429-3439.
5. Chudnovsky Y, Khavari PA, Adams AE. 2005. Melanoma genetics and the development of rational therapeutics. J Clin Invest 115:813-824.
6. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Brocker EB, LeBoit PE, Pinkel D, Bastian BC. 2005. Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147.
7. Curtin JA, Busam K, Pinkel D, Bastian BC. 2006. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. 2002. Mutations of the BRAF gene in human cancer. Nature 417:949-954.
9. Eskandarpour M, Kiaii S, Zhu C, Castro J, Sakko AJ, Hansson J. 2005. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer 115:65-73.
10. Fecher LA, Cummings SD, Keefe MJ, Alani RM. 2007. Toward a molecular classification of melanoma. J Clin Oncol 25:1606-1620.
11. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG. 2006. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6:96.
12. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, Gauger P, Doherty G, Thompson NW, Hanash S, Koenig RJ, Nikiforov YE. 2005. Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24:6646-6656.
13. Greshock J, Naylor TL, Margolin A, Diskin S, Cleaver SH, Futreal PA, deJong PJ, Zhao S, Liebman M, Weber BL. 2004. 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. Genome Res 14:179-187.
14. Greshock J, Feng B, Nogueira C, Ivanova E, Perna I, Nathanson K, Protopopov A, Weber BL, Chin L. 2007a. A comparison of DNA copy number profiling platforms. Cancer Res 67:10173-10180.
15. Greshock J, Nathanson K, Martin AM, Zhang L, Coukos G, Weber BL, Zaks TZ. 2007b. Cancer cell lines as genetic models of their parent histology: Analyses based on array comparative genomic hybridization. Cancer Res 67:3594-3600.
16. Guo W, Wu S, Liu J, Fang B. 2008. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota. Cancer Res 68:7403-7408.
17. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. 2003. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63:5198-5202.
18. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S. 2006. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 66:999-1006.
19. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghlul S, McNamara K, Chen L, Albert M, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Janne PA, Johnson BE, Chin L, Wong KK. 2007. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 67:4933-4939.
20. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD. 2008. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 105:4283-4288.
21. Jonsson G, Dahl C, Staaf J, Sandberg T, Bendahl PO, Ringner M, Guldberg P, Borg A. 2007. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 26:4738-4748.
22. Kabbarah O, Chin L. 2005. Revealing the genomic heterogeneity of melanoma. Cancer Cell 8:439-441.
23. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, Flotte TJ, Duncan LM, Granter SR, Chin L. 2006. Comparative onco- genomics identifies NEDD9 as a melanoma metastasis gene. Cell 125:1269-1281.
24. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Mar- mion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. 2008. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 68:664-673.
25. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, Kageshita T, Ono T, Albertson DG, Pinkel D, Bastian BC. 2003. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 95:1878-1890.
26. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. 2007. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104:19936-19941.
27. Neben K, Schnittger S, Brors B, Tews B, Kokocinski F, Haferlach T, Muller J, Hahn M, Hiddemann W, Eils R, Lichter P, Schoch C. 2005. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 24:1580-1588.
28. Olshen AB, Venkatraman ES, Lucito R, Wigler M. 2004. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557-572.
29. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. 2003. NRAS and BRAF mutations arise early during melanoma patho- genesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483-6488.
30. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, Walker GJ, Boyle GM, Harper U, Cozzi SJ, Hansen K, Yudt L, Schmidt C, Hersey P, Ellem KA, O'Rourke MG, Parsons PG, Meltzer P, Ringner M, Hayward NK. 2004. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23:4060-4067.
31. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. 2003. High frequency of BRAF mutations in nevi. Nat Genet 33:19-20.
32. Poynter JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE, Gruber SB. 2006. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267-273.
33. Roberts JD. 2006. E2F1 amplification and genetic heterogeneity in melanoma. Cancer Biol Ther 5:691-692.
34. Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE. 2007. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res 67:1502-1512.
35. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. 2006. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362.
36. Tanami H, Imoto I, Hirasawa A, Yuki Y, Sonoda I, Inoue J, Yasui K, Misawa-Furihata A, Kawakami Y, Inazawa J. 2004. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene 23:8796-8804.
37. Tomasini R, Mak TW, Melino G. 2008. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 18:244-252.
38. ribe P, Wistuba II, Gonzalez S. 2003. BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 25:365-370.
39. Willmore-Payne C, Holden JA, Hirschowitz S, Layfield LJ. 2006. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37:520-527.
40. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S, Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O'Brien-Jenkins A, Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G. 2006. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 103:9136-9141.